BACKGROUND: Identification of clients at greatest risk of acquiring HIV is critical for preexposure prophylaxi (PrEP) implementation. Young black MSM (YBMSM) have high incidence of HIV. We examined published guidelines in identifying eligible PrEP candidates, including seroconverters, in a representative cohort of YBMSM. METHODS: The uConnect cohort included YBMSM aged 16-29 years during PrEP roll-out in Chicago from 2013 and 2016. YBMSM with indications for PrEP were determined using Center for Disease Control and Prevention (CDC) guidelines, the HIV incidence risk index for MSM (HIRI-MSM) scoring tool, and Gilead recommendations with calculation of sensitivities, specificities, and area under the curve (AUC) for HIV seroconversion over 18 months. Incidence rate ratios (IRRs) using Poisson regression were modeled to compare individual and network factors associated with seroconversion. RESULTS: In the study cohort, 300 HIV uninfected YBMSM contributed 390.4 person-years of follow-up [mean age (SD), 22.3 years (3.07)]. HIV incidence was 8.5 cases per 100 person-years (95% confidence interval, 6.0-11.9). One network factor was associated with seroconversion: having partners more than 10 years older (IRR = 4.4, 95% confidence interval, 1.6-11.8). Overall, 49% of the cohort had an indication for PrEP using CDC guidelines; 72% using HIRI-MSM, and 86% using Gilead recommendations. HIV seroconverters (n = 33) were identified as PrEP eligible prior to seroconversion with sensitivities/AUCs for CDC (52%/0.51), HIRI-MSM (85%/0.57), and Gilead guidelines (94%/0.54). CONCLUSION: Low sensitivity of CDC guidelines and limited AUC of HIRI-MSM and Gilead screening tools are of concern for PrEP implementation among most at risk populations such as YBMSM. Consideration of demographics, local epidemiology, and network factors may better guide identification of clients who could benefit most from PrEP.
BACKGROUND: Identification of clients at greatest risk of acquiring HIV is critical for preexposure prophylaxi (PrEP) implementation. Young black MSM (YBMSM) have high incidence of HIV. We examined published guidelines in identifying eligible PrEP candidates, including seroconverters, in a representative cohort of YBMSM. METHODS: The uConnect cohort included YBMSM aged 16-29 years during PrEP roll-out in Chicago from 2013 and 2016. YBMSM with indications for PrEP were determined using Center for Disease Control and Prevention (CDC) guidelines, the HIV incidence risk index for MSM (HIRI-MSM) scoring tool, and Gilead recommendations with calculation of sensitivities, specificities, and area under the curve (AUC) for HIV seroconversion over 18 months. Incidence rate ratios (IRRs) using Poisson regression were modeled to compare individual and network factors associated with seroconversion. RESULTS: In the study cohort, 300 HIV uninfected YBMSM contributed 390.4 person-years of follow-up [mean age (SD), 22.3 years (3.07)]. HIV incidence was 8.5 cases per 100 person-years (95% confidence interval, 6.0-11.9). One network factor was associated with seroconversion: having partners more than 10 years older (IRR = 4.4, 95% confidence interval, 1.6-11.8). Overall, 49% of the cohort had an indication for PrEP using CDC guidelines; 72% using HIRI-MSM, and 86% using Gilead recommendations. HIV seroconverters (n = 33) were identified as PrEP eligible prior to seroconversion with sensitivities/AUCs for CDC (52%/0.51), HIRI-MSM (85%/0.57), and Gilead guidelines (94%/0.54). CONCLUSION: Low sensitivity of CDC guidelines and limited AUC of HIRI-MSM and Gilead screening tools are of concern for PrEP implementation among most at risk populations such as YBMSM. Consideration of demographics, local epidemiology, and network factors may better guide identification of clients who could benefit most from PrEP.
Authors: Colleen F Kelley; Erin Kahle; Aaron Siegler; Travis Sanchez; Carlos Del Rio; Patrick S Sullivan; Eli S Rosenberg Journal: Clin Infect Dis Date: 2015-08-13 Impact factor: 9.079
Authors: Neil M Flynn; Donald N Forthal; Clayton D Harro; Franklyn N Judson; Kenneth H Mayer; Michael F Para Journal: J Infect Dis Date: 2005-01-27 Impact factor: 5.226
Authors: Lisa A Eaton; Daniel D Driffin; Jose Bauermeister; Harlan Smith; Christopher Conway-Washington Journal: AIDS Patient Care STDS Date: 2015-06-17 Impact factor: 5.078
Authors: Ethan Morgan; Britt Skaathun; Stuart Michaels; Lindsay Young; Aditya Khanna; Samuel R Friedman; Billy Davis; David Pitrak; John Schneider Journal: AIDS Behav Date: 2016-03
Authors: Curtis Dolezal; Timothy Frasca; Rebecca Giguere; Mobolaji Ibitoye; Ross D Cranston; Irma Febo; Kenneth H Mayer; Ian McGowan; Alex Carballo-Diéguez Journal: AIDS Educ Prev Date: 2015-08
Authors: Patrick S Sullivan; Eli S Rosenberg; Travis H Sanchez; Colleen F Kelley; Nicole Luisi; Hannah L Cooper; Ralph J Diclemente; Gina M Wingood; Paula M Frew; Laura F Salazar; Carlos Del Rio; Mark J Mulligan; John L Peterson Journal: Ann Epidemiol Date: 2015-03-24 Impact factor: 3.797
Authors: Moira McNulty; J D Smith; Juan Villamar; Inger Burnett-Zeigler; Wouter Vermeer; Nanette Benbow; Carlos Gallo; Uri Wilensky; Arthur Hjorth; Brian Mustanski; John Schneider; C Hendricks Brown Journal: Ethn Dis Date: 2019-02-21 Impact factor: 1.847
Authors: Lisa A Eaton; Derrick D Matthews; Leigh A Bukowski; M Ruvel Friedman; Cristian J Chandler; Darren L Whitfield; Jordan M Sang; Ron D Stall Journal: J Acquir Immune Defic Syndr Date: 2018-11-01 Impact factor: 3.731
Authors: Julia L Marcus; Leo B Hurley; Douglas S Krakower; Stacey Alexeeff; Michael J Silverberg; Jonathan E Volk Journal: Lancet HIV Date: 2019-07-05 Impact factor: 12.767
Authors: Hyman Scott; Eric Vittinghoff; Risha Irvin; Albert Liu; LaRon Nelson; Carlos Del Rio; Manya Magnus; Sharon Mannheimer; Sheldon Fields; Hong Van Tieu; Irene Kuo; Steve Shoptaw; Beatriz Grinsztejn; Jorge Sanchez; Steven Wakefield; Jonathan D Fuchs; Darrell Wheeler; Kenneth H Mayer; Beryl A Koblin; Susan Buchbinder Journal: AIDS Behav Date: 2020-01
Authors: Anna L Hotton; Yen-Tyng Chen; Phil Schumm; Aditya S Khanna; Russell Brewer; Britt Skaathun; Rodal S Issema; Santhoshini Ramani; Arthi Ramachandran; Jonathan Ozik; Kayo Fujimoto; Nina T Harawa; John A Schneider Journal: J Urban Health Date: 2020-10 Impact factor: 3.671